

WHY CHOOSE ExomeNext

Whole exome sequencing (WES) looks at the DNA where 85% of known genetic variations reside and may indicate a disease-causing mutation. ExomeNext provides a clear picture of a patient's health in a timely and cost-effective manner that can lead to better patient outcomes quickly and cost-effectively.

BENEFIT	WHY THIS MATTERS
<p>High Diagnostic Rate</p> <p>WES is 2-3 times more likely to identify the underlying genetic defect than traditional tests</p>	<ul style="list-style-type: none"> A diagnosis brings an end to the expensive, time-consuming, and potentially invasive diagnostic odyssey that burdens patients, families, and the healthcare system. The diagnostic rate for WES ranges from 25-35% based on published literature.¹⁻⁸ The rate is 2-3 times as likely as traditional methods (single gene, panels, etc.) to identify the underlying cause of a patient's genetic disease.⁹⁻¹³ Exome sequencing reanalysis following an originally negative report is more cost-effective and results in a much better diagnostic rate than further genetic testing.¹⁴ The rate is continually increasing due to the rapid rate of new gene-disease discoveries.^{2,15} Today, a peer-reviewed study reporting a newly-discovered disease gene is published every other day on average.¹⁵
<p>Impacts Medical Management</p> <p>Positive results alter medical management for virtually all patients</p>	<ul style="list-style-type: none"> An early and accurate diagnosis can lead to optimal care and dramatic prognostic improvements for patients and their families.^{6,7,16-20} One clinic recently reported that medical management was impacted for 100% of their patients with positive WES results.⁶ Clinical utility benefits include: <ul style="list-style-type: none"> Tailored medical management^{6,18,20,21,24} Prophylactic therapy²³ Minimization of invasive diagnostic procedures (i.e. muscle biopsies, MRIs w/ anesthesia)^{7,20} Reproductive planning^{6,18,20,21,24} Eligibility for clinical trials^{7,8}
<p>Cost Effective</p> <p>WES is about half to one-quarter the cost compared to traditional genetic tests</p>	<ul style="list-style-type: none"> WES is 25-50% the cost of traditional genetic testing trajectory.^{13,21,24} Several studies show WES as a first line approach vs. standard clinical practice saves \$1,000-\$7,640 per case.^{11,13,22} Identification of the underlying cause of genetic disease leads to informed family planning; this reduces costs as family members can then undergo less expensive targeted single site analysis.²² Targeted treatment options improve patients' conditions and also reduce costly hospital fees, along with wasteful non-effective treatment modalities.^{7,20}

ABOUT THE TEST

Ambry's ExomeNext™ is performed using whole exome sequencing, a robust technology that sequences all of the functionally relevant regions of essentially all 20,000 genes of the human genome. The beauty of this test is that it has the capacity to pinpoint rare mutations in an unbiased and efficient way. WES in a diagnostic setting is the most cost-effective and comprehensive method to rapidly detect the underlying etiology in patients with genetic disease.^{10-13,22,25}

REFERENCES

1. Farwell KD, Shahmirzadi L, El-Khechen D, *et al.* Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2015;17(7):578-586.
2. Farwell Hagman KD, Shinde DN, Mroske C, *et al.* Candidate-gene criteria for clinical reporting: diagnostic exome sequencing identifies altered candidate genes among 8% of patients with undiagnosed diseases. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2016.
3. Yang Y, Muzny DM, Reid JG, *et al.* Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *The New England journal of medicine.* 2013;369(16):1502-1511.
4. Yang Y, Muzny DM, Xia F, *et al.* Molecular findings among patients referred for clinical whole-exome sequencing. *Jama.* 2014;312(18):1870-1879.
5. Lee H, Deignan JL, Dorrani N, *et al.* Clinical exome sequencing for genetic identification of rare Mendelian disorders. *Jama.* 2014;312(18):1880-1887.
6. Srivastava S, Cohen JS, Vernon H, *et al.* Clinical whole exome sequencing in child neurology practice. *Annals of neurology.* 2014;76(4):473-483.
7. Iglesias A, Anyane-Yeboah K, Wynn J, *et al.* The usefulness of whole-exome sequencing in routine clinical practice. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2014.
8. Retterer K, Juusola J, Cho MT, *et al.* Clinical application of whole-exome sequencing across clinical indications. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2016;18(7):696-704.
9. Shashi V, McConkie-Rosell A, Rosell B, *et al.* The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2013.
10. Vissers LE, van Nimwegen KJ, Schieving JH, *et al.* A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2017.
11. Stark Z, Schofield D, Alam K, *et al.* Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2017;19(8):867-874.
12. Gomez CM, Das S. Clinical exome sequencing: the new standard in genetic diagnosis. *JAMA Neurol.* 2014;71(10):1215-1216.
13. Monroe GR, Frederix GW, Savelberg SM, *et al.* Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2016;18(9):949-956.
14. Stark Z, Schofield D, Martyn M, *et al.* Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2018.
15. Boycott KM, Rath A, Chong JX, *et al.* International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. *American journal of human genetics.* 2017;100(5):695-705.
16. Worthey EA, Mayer AN, Syverson GD, *et al.* Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2011;13(3):255-262.
17. Fogel BL, Lee H, Deignan JL, *et al.* Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. *JAMA Neurol.* 2014;71(10):1237-1246.
18. Hanchard NA, Murdock DR, Magoulas PL, *et al.* Exploring the utility of whole-exome sequencing as a diagnostic tool in a child with atypical episodic muscle weakness. *Clinical genetics.* 2013;83(5):457-461.
19. Fan Z, Greenwood R, Felix AC, *et al.* GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia. *J Neurol.* 2014;261(3):622-624.
20. Sawyer SL, Hartley T, Dyment DA, *et al.* Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. *Clinical genetics.* 2016;89(3):275-284.
21. Dixon-Salazar TJ, Silhavy JL, Udpa N, *et al.* Exome sequencing can improve diagnosis and alter patient management. *Science translational medicine.* 2012;4(138):138ra178.
22. Soden SE, Saunders CJ, Willig LK, *et al.* Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. *Science translational medicine.* 2014;6(265):265ra168.
23. Raffan E, Hurst LA, Turki SA, *et al.* Early Diagnosis of Werner's Syndrome Using Exome-Wide Sequencing in a Single, Atypical Patient. *Front Endocrinol (Lausanne).* 2011;2:8.
24. Martin HC, Kim GE, Pagnamenta AT, *et al.* Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. *Human molecular genetics.* 2014;23(12):3200-3211.
25. Tan TY, Dillon OJ, Stark Z, *et al.* Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions. *JAMA Pediatr.* 2017.